Welcome to our dedicated page for Dexcom SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DexCom, Inc. (DXCM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q when filed. Dexcom is listed on the Nasdaq Stock Market under the symbol DXCM, and its SEC filings offer detailed information on financial performance, governance, and material events related to its glucose biosensing and continuous glucose monitoring (CGM) business.
Recent Form 8-K filings illustrate how Dexcom uses SEC reports to communicate key developments. For example, the company has filed 8-Ks to furnish quarterly financial results, including revenue by geography and product component, and to describe leadership transitions such as the appointment of Jacob S. Leach as President and Chief Executive Officer and the appointment of Dr. Euan Ashley to the Board of Directors. These filings also document changes in board size, committee assignments, and executive roles.
Dexcom’s periodic reports, including 10-K and 10-Q filings when available, typically contain audited financial statements, discussions of sensor and hardware revenue, descriptions of its CGM and biosensing operations, and risk factor disclosures. Investors can also review sections on research and development spending, capital structure, and non-GAAP performance metrics that the company discusses alongside GAAP results in its earnings-related 8-Ks.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, margin commentary, governance updates, and other material items. Users can also monitor items related to director and executive appointments or departures, and other reportable events under Form 8-K. This page is a central resource for analyzing Dexcom’s regulatory history and for tracking how financial and governance information evolves over time.
Kyle Malady, a director of DexCom, Inc. (DXCM), reported a sale of common stock executed on 09/05/2025 under a previously adopted 10b5-1 trading plan. The Form 4 shows 667 shares were sold at $80.86 per share pursuant to the 10b5-1 plan adopted on 06/06/2025 to allow orderly dispositions. After the reported sale, Mr. Malady beneficially owned 22,667 shares, which include 5,192 unvested restricted stock units granted on 05/08/2025 that vest on the earlier of the one-year anniversary of the grant or DexCom’s 2026 Annual Meeting of Stockholders.
Sadie Stern, EVP and Chief HR Officer of DexCom, Inc. (DXCM), reported a sale of common stock under a pre-established plan. On 09/04/2025 Ms. Stern disposed of 1,466 shares at $80.00 per share pursuant to a 10b5-1 trading plan adopted on 02/20/2025 to allow orderly dispositions. After the reported sale she beneficially owns 105,223 shares in total. That total includes 74,450 unvested restricted stock units with detailed vesting: 29,922 RSUs granted 03/08/2025 vesting through 03/08/2028; 22,798 RSUs granted 03/08/2025 vesting through 03/08/2027; 14,474 RSUs granted 03/08/2024 vesting through 03/08/2027; and 7,256 RSUs granted 03/08/2023 vesting through 03/08/2026. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
DexCom insider notification: A person affiliated with DexCom, Inc. (DXCM) indicated a proposed sale of 667 common shares through Fidelity Brokerage Services with an aggregate market value of $53,933.62. The filing lists approximately 392,155,265 shares outstanding and an approximate sale date of 09/05/2025. The securities were acquired on 05/18/2024 via restricted stock vesting and paid as compensation. The filer reports no securities sold in the past three months and makes the Rule 144 representation that they are not aware of undisclosed material adverse information about the issuer.
DexCom Form 144 summary: This notice reports proposed sales of 1,466 shares of DexCom common stock to be executed through Morgan Stanley Smith Barney LLC on 09/04/2025 on NASDAQ, with an aggregate market value listed at $117,280.00. The filings show the same filer, Sadie Stern, sold 1,466 shares on 07/28/2025 for $130,459.34 and 1,466 shares on 06/26/2025 for $124,697.96 during the past three months. The securities to be sold were originally acquired as restricted stock from the issuer on 12/15/2023 (978 shares) and 11/19/2023 (488 shares). The filer affirms no undisclosed material adverse information.
DexCom insider sale under 10b5-1 plan: Sylvain Jereme M., Executive Vice President and Chief Financial Officer of DexCom (DXCM), reported the sale of 4,824 shares of DexCom common stock on 09/02/2025 at an average price of $74.17 per share. The filing states the sales were made pursuant to a 10b5-1 trading plan adopted on May 27, 2025 to allow orderly dispositions. After the reported disposition, Mr. Sylvain beneficially owns 118,657 shares, which include 83,328 unvested restricted stock units with scheduled vesting through March 8, 2028.
Form 144 filed for DexCom, Inc. (DXCM) proposing the sale of 4,824 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ at an aggregate market value of $357,796.08. The filing lists acquisition details for the shares: 3,464 shares received as restricted stock on 03/08/2023, 696 shares acquired via an employee stock purchase plan on 08/30/2019 (cash), and 664 shares from an employee stock purchase plan on 02/28/2020 (cash). The filer states there have been no securities sold in the past three months for the account and affirms no undisclosed material adverse information. The notice identifies the broker and gives the number of shares outstanding as 392,155,265.
DexCom insider sale under pre-established plan; small number of shares sold. Michael Jon Brown, EVP and Chief Legal Officer of DexCom (DXCM), sold 500 shares of common stock on 08/15/2025 at a reported price of $80.29 per share. The sale was executed pursuant to a 10b5-1 trading plan adopted on 02/21/2025, which the filing states allows for orderly dispositions of his shares.
After the reported sale Mr. Brown beneficially owned 94,102 shares. The filing discloses that 86,490 of those shares are unvested restricted stock units, detailed by grant dates and vesting schedules (grants from 2022–2025 with vesting through March 8, 2028). The form is signed by an attorney-in-fact on 08/18/2025.
Mark G. Foletta, a trustee and director of DexCom, Inc. (DXCM), reported sales of company stock executed on 08/15/2025 under a pre-existing 10b5-1 plan. The filing shows two sale transactions: 2,555 shares sold at a weighted average price of $81.0186 (individual trade prices ranged $80.29–$81.22) and 195 shares sold at $81.54. After these transactions, the filing reports beneficial holdings by The Foletta Family Trust of 51,316 and 51,121 shares respectively. The report also discloses 5,731 unvested restricted stock units granted on May 8, 2025 that will vest on the earlier of the one-year anniversary of the grant or DexCom’s 2026 annual meeting.
Form 144 notice for proposed sale of securities under Rule 144. The filing shows an intended sale of 500 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $40,145, slated for 08/15/2025 on NASDAQ. The shares were acquired as restricted stock on 03/08/2024 from the issuer and paid in full on that date. The filing also reports three sales by the same person in the past three months totaling 11,000 shares for gross proceeds of $920,264. The filing identifies the seller in prior sales as Michael Brown.
DexCom (DXCM) Form 144 notice reports a proposed sale of 2,750 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $220,797.50 and approximately 392,155,265 shares outstanding. The shares were acquired as vested RSUs on 05/19/2022 and payment was recorded the same day. The filer notes an approximate sale date of 08/15/2025. The filing also discloses two prior sales by the same account: 2,750 shares on 06/16/2025 for $228,604.75 and 2,750 shares on 07/15/2025 for $234,216.67. The notice includes standard Rule 144 representations but contains no entered dates or signature data in the remarks section.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
